Characterization Of Antibodies Targeting Aso Modifications For Intracellular Trafficking

Peter Oliver and Xiao Wan, from nan Research Complex astatine Harwell, U.K., and coauthors, validated caller panels of antibody reagents that target clinically applicable nucleic acid modifications for visualizing ASOs some successful vitro and successful vivo. The investigators tested ASOs successful vitro for intracellular localization by immunocytochemistry and for biodistribution successful rodent tissues by immunohistochemistry.

"Our information show nan inferior of these reagents for nan NAT field, wherever modified nucleic acids tin beryllium detected irrespective of nan nucleotide sequence, rendering nan strategy amenable for aggregate objective and pre-clinical workflows and quantitative immunoassays," stated nan investigators.

"Advancing expedited preclinical improvement requires amended devices to trace nan biodistribution of imaginable oligonucleotide therapeutics successful vivo to bring them to nan objective arena," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Source:

Journal reference:

Fial, I., et al. (2025). Characterizing Antibodies Targeting Antisense Oligonucleotide Phosphorothioate and 2′-O-Methoxyethyl Modifications for Intracellular Trafficking and Biodistribution Studies. Nucleic Acid Therapeutics. doi.org/10.1177/21593337251361396.